Vanessa Bianconi1,2, Massimo Raffaele Mannarino1,2, Amirhossein Sahebkar3, Teresa Cosentino1,2, Matteo Pirro4,5. 1. Unit of Internal Medicine, Department of Medicine, University of Perugia, Perugia, Italy. 2. Hospital "Santa Maria della Misericordia", Piazzale Menghini, 1, 06129, Perugia, Italy. 3. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Unit of Internal Medicine, Department of Medicine, University of Perugia, Perugia, Italy. matteo.pirro@unipg.it. 5. Hospital "Santa Maria della Misericordia", Piazzale Menghini, 1, 06129, Perugia, Italy. matteo.pirro@unipg.it.
Abstract
PURPOSE OF REVIEW: The aim of this review is to provide an update on the effects of the dietary supplementation with cholesterol-lowering nutraceuticals and nutraceutical combinations affecting vascular function and CV risk in clinical interventional studies. RECENT FINDINGS: Current evidence supports the mild-to-moderate cholesterol-lowering efficacy of red yeast rice, berberine, plant sterols, fibers, and some nutraceutical combinations whereas data on the individual cholesterol-lowering action of other nutraceuticals are either less striking or even inconclusive. There is also promising evidence on the vascular protective effects of some of the aforementioned nutraceuticals. However, except for red yeast rice, clinical interventional studies have not investigated their impact on CV outcomes. Evidence of both cholesterol-lowering and vascular protection is a prerogative of few single nutraceuticals and nutraceutical combinations, which may support their clinical use; however, caution on their uncontrolled adoption is necessary as they are freely available on the market and, therefore, subject to potential misuse.
PURPOSE OF REVIEW: The aim of this review is to provide an update on the effects of the dietary supplementation with cholesterol-lowering nutraceuticals and nutraceutical combinations affecting vascular function and CV risk in clinical interventional studies. RECENT FINDINGS: Current evidence supports the mild-to-moderate cholesterol-lowering efficacy of red yeastrice, berberine, plant sterols, fibers, and some nutraceutical combinations whereas data on the individual cholesterol-lowering action of other nutraceuticals are either less striking or even inconclusive. There is also promising evidence on the vascular protective effects of some of the aforementioned nutraceuticals. However, except for red yeastrice, clinical interventional studies have not investigated their impact on CV outcomes. Evidence of both cholesterol-lowering and vascular protection is a prerogative of few single nutraceuticals and nutraceutical combinations, which may support their clinical use; however, caution on their uncontrolled adoption is necessary as they are freely available on the market and, therefore, subject to potential misuse.
Authors: H V T Ho; J L Sievenpiper; A Zurbau; S Blanco Mejia; E Jovanovski; F Au-Yeung; A L Jenkins; V Vuksan Journal: Eur J Clin Nutr Date: 2016-06-08 Impact factor: 4.016
Authors: Peter P Toth; Angelo M Patti; Dragana Nikolic; Rosaria V Giglio; Giuseppa Castellino; Teresa Biancucci; Fabiana Geraci; Sabrina David; Giuseppe Montalto; Ali Rizvi; Manfredi Rizzo Journal: Front Pharmacol Date: 2016-01-06 Impact factor: 5.810
Authors: Parag A Chevli; Amer I Aladin; Alka M Kanaya; Namratha R Kandula; Diego Malaver; David M Herrington Journal: Nutr Metab Cardiovasc Dis Date: 2019-07-31 Impact factor: 4.222